This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer.
Number of pages:12
This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer. Ibrance (palbociclib; PFE) was granted accelerated approval by the FDA in February 2015, and its label currently includes the patient population also commonly treated with Afinitor (everolimus; NVS). Although Ibrance demonstrated a strong improvement in median progression- free survival (PFS) in the registrational, Phase II PALOMA-1 trial, the drug did not strongly improve overall survival (OS), and patients had a high rate of neutropenia. However, the effect of this drug on OS may be confounded by subsequent treatments received by patients in the placebo arm, and OS was not the primary endpoint for this study.
Other drugs covered in this survey are the following: Halaven (eribulin; Eisai), Abraxane (nab-paclitaxel; CELG), Doxil (pegylated liposomal doxorubicin; JNJ), Gemzar (gemcitabine; LLY), and Xeloda (capecitabine; Roche).
Question 1: In the last three months, how many patients did you see in the following subgroups? Please include all patients in each subgroup, including patients not actively receiving treatment (i.e. in follow-up after treatment [free numerical response for each choice]
Question 2: In the last three months, how many of your patients with metastatic or locally advanced, HR+/HER2- breast cancer received the following regimens: [free numerical response for each choice]
Question 3: In the next 12 months, how often will you prescribe the following regimens to patients with metastatic or locally advanced, HR+/HER2- breast cancer in the following lines of treatment? (1 = least usage, 4 = most usage)
Question 4: How strongly do the following factors affect your palbociclib prescribing practices? 1=factor doesn’t affect my prescribing at all, 4=factor strongly affects my prescribing
Question 5: Please describe your overall usage of the following agents for the treatment of patients with metastatic or locally advanced breast cancer. Please consider patients of all receptor subtypes, not just HR+/HER2-.
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726